Pyxis Oncology, Inc. (PYXS)
| Market Cap | 106.81M |
| Revenue (ttm) | 13.86M |
| Net Income (ttm) | -79.62M |
| Shares Out | 62.83M |
| EPS (ttm) | -1.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 295,660 |
| Open | 1.760 |
| Previous Close | 1.760 |
| Day's Range | 1.680 - 1.870 |
| 52-Week Range | 0.970 - 5.550 |
| Beta | 1.42 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+311.77%) |
| Earnings Date | May 14, 2026 |
About PYXS
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-o... [Read more]
Financial Performance
In 2025, Pyxis Oncology's revenue was $13.86 million, a decrease of -14.17% compared to the previous year's $16.15 million. Losses were -$79.62 million, 2.96% more than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for PYXS stock is "Strong Buy." The 12-month stock price target is $7.0, which is an increase of 311.77% from the latest price.
News
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quar...
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leader...
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial
Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell carcinom...
Pyxis Oncology Transcript: Study Update
MCVO demonstrated strong preliminary efficacy and manageable safety in both monotherapy and combination with pembrolizumab for recurrent/metastatic head and neck cancer, with high response and disease control rates across diverse patient backgrounds. Adjusted Ideal Body Weight dosing is being implemented to further optimize safety, and pivotal studies are planned with FDA alignment.
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced positive...
Pyxis Oncology Transcript: Stifel 2025 Healthcare Conference
The lead ADC asset demonstrated strong efficacy and safety in early trials, especially in head and neck cancer, with broad tumor regression and durable responses. Expansion trials target key resistant populations and combination strategies, with year-end data expected to inform competitive positioning and regulatory plans.
Pyxis Oncology Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
MICVO, a non-internalizing ADC, is advancing in head and neck cancer with promising phase I results, including a 50% response rate and strong tolerability. Upcoming Q4 data will cover both monotherapy and combination cohorts, aiming to meet or exceed a 35% ORR benchmark in a competitive landscape.
Pyxis Oncology to Participate in Upcoming Investor Conferences
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that man...
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the f...
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
Translational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pelidotin (MICVO) MICVO combats solid tumors through three-pronged mechanism of action: direct tumor ce...
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today anno...
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC') therapeutics for difficult-to-treat ...
Pyxis Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference
MICO, an ADC targeting EDB, is prioritized for head and neck cancer with monotherapy and combination trials, aiming for key data readouts in the next 12 months. Early efficacy and safety data are promising, and the company is well-funded through upcoming catalysts.
Pyxis Oncology Transcript: Cantor Global Healthcare Conference 2025
MICVO, an extracellular targeting ADC, is showing strong efficacy in head and neck cancer, especially in heavily pretreated patients, with a favorable safety profile and broad applicability across subgroups. Upcoming data from expansion cohorts and combination studies with pembrolizumab will further define its competitive positioning.
Pyxis Oncology to Participate in September Investor and Industry Conferences
BOSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today anno...
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
– Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data i...
Pyxis Oncology Transcript: Jefferies Global Healthcare Conference 2025
MICVO, an extracellular targeting ADC, showed a 50% ORR in heavily pretreated head and neck cancer patients with a strong safety profile. Key data readouts for monotherapy and combo studies are expected in 2H 2024 and 1H 2025, with ongoing translational research and a solid cash runway.
Pyxis Oncology Transcript: RBC Capital Markets Global Healthcare Conference 2025
MICVO, a novel ADC, has shown promising tumor regression and disease control across multiple tumor types, with a particularly strong signal in head and neck cancer. Safety profile is favorable, and upcoming data from expanded monotherapy and combination trials are expected to further validate efficacy and broaden clinical potential.
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
- Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, b...
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that ...
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-...
Pyxis Oncology Transcript: Stifel 2025 Virtual Targeted Oncology Forum
A single-asset strategy is underway, focusing on MICVO, an extracellular ADC showing strong efficacy and safety in head and neck cancer. Mechanistic innovation is validated by recent scientific advances, and upcoming data will further clarify its clinical potential.
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that La...
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated with efficacy, deepening understanding of MOA and potenti...